Praxis Precision Medicines, Inc. research snapshot
PRAX AI stock analysis reads Praxis Precision Medicines as a clinical-stage CNS biotech whose value now rests on two NDAs under FDA review (relutrigine for SCN2A/SCN8A DEE and ulixacaltamide for essential tremor) plus a Breakthrough Therapy Designation for elsunersen, after the June 1, 2026 POWER1 Phase 2/3 miss forced the company to pause enrollment in the vormatrigine POWER2 study. As of the August 3, 2026 data cutoff, PRAX traded at $307.83, about 16% below its all-time high of $366.52, with a verified market capitalization of about $8.58 billion. Analyst consensus stays bullish (16 of 18 Google Finance ratings are Buy, with an average target of $601.59), but the stock carries binary regulatory, clinical, and commercialization risk, no revenue, and ongoing operating losses. This page is informational research, not investment advice.
Current price
$307.83
Market cap
About $8.58 billion using Google Finance shares outstanding
AI score
50 / 100
Rating
Multimodal CNS pipeline with two NDAs under FDA review, offset by a Phase 2/3 miss and a demanding pre-revenue valuation
Trend status
Down about 16% from the all-time high of $366.52 after the June 1 POWER1 miss, now consolidating in a $290 to $330 range
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Praxis is a clinical-stage biotech developing precision therapies for CNS disorders including essential tremor, genetic epilepsies, and movement disorders. Business quality is unproven until at least one program gains FDA approval and commercial adoption. | Low-medium |
| Moat | Potential moat from proprietary Cerebrum small molecule and Solidus ASO platforms, three FDA Breakthrough Therapy Designations, and differentiated mechanisms of action. The weak point is that large pharma competitors have deep neurology pipelines and can outspend Praxis on clinical development and commercialization. | Low |
| Management | Management raised capital to reach $786.87 million in cash and investments, advanced two NDAs to FDA review, and secured a Breakthrough Therapy Designation for elsunersen. However, the company has no commercial experience and must now manage FDA interactions and, if approved, build a launch infrastructure or find partners. | Medium |
| Financial trend | No revenue. Operating expenses grew from about $76 million in the June 2025 quarter to $105.86 million in the March 2026 quarter as the pipeline expanded. Q1 2026 net loss was $92.56 million and TTM net loss was about $326.53 million, with about $282 million of TTM free cash flow burn. | High |
| Valuation | At $307.83 and $8.58 billion market cap, the stock is valued on pipeline probability, not current earnings. With TTM EPS of about -$13.37, conventional PE analysis does not apply. Net cash of about $785 million covers only about 10% of the market cap, so the valuation implies a high probability of NDA and FDA success. | Medium |
| Technical trend | PRAX fell about 23% on June 2, 2026 after the POWER1 miss, bottomed near $240, rebounded to about $350 by June 29, then consolidated in a $287 to $330 range through July. The stock is now trading around the middle of that range near $308. | Medium |
| Risk level | Risk is very high. FDA complete response letters, clinical trial failure, safety signals, competitive pipeline developments, shareholder dilution, and cash runway constraints are all material risks. The stock can gap 20-30% on a single FDA or clinical event, as it did on June 2, 2026. | High |
| AI confidence | High for historical quote data, share count, market cap verification, and cash burn math. Low for forward clinical outcomes and regulatory scenarios, which depend on FDA review of relutrigine and ulixacaltamide. | Low data confidence |
| Investment certainty | Very low. Binary risk events (FDA decisions, clinical data) dominate the return profile for PRAX. Even the most well-researched pipeline analysis cannot resolve the fundamental uncertainty of NDA review outcomes and Phase 3 results. | Very low |
PRAX AI stock forecast
The PRAX AI stock forecast uses scenario ranges around the $307.83 quote. Because PRAX has no revenue or earnings, conventional valuation models do not apply. The scenarios below reflect potential outcomes based on NDA review progress (relutrigine PDUFA December 27, 2026 and ulixacaltamide PDUFA January 29, 2027), analyst target dispersion, and the binary nature of biotech investing.
$500 to $1,200
More likely if relutrigine is approved on or around its December 27, 2026 PDUFA date, ulixacaltamide receives a positive FDA outcome near its January 29, 2027 PDUFA date, elsunersen continues to show strong data in EMBRAVE3, and the higher analyst targets such as Piper Sandler $1,200, H.C. Wainwright $1,201, and LifeSci Capital $719 prove achievable.
$300 to $450
More likely if FDA review proceeds without a complete response letter, the stock tracks toward the lower analyst targets such as Goldman Sachs $447, RBC Capital $449, and Wells Fargo $323, cash runway stays above 12 months, and the stock continues to trade inside its recent $290 to $330 consolidation range with normal volatility.
$162 to $290
More likely if FDA issues a complete response letter for relutrigine or ulixacaltamide, vormatrigine is discontinued after the POWER1 miss, a competitor advances a superior therapy, safety concerns emerge, or the company needs dilutive financing. The Wedbush sell-side target of $162 marks a potential downside area, and the June 2026 low near $240 is an intermediate stop.
PRAX AI technical analysis
PRAX AI technical analysis is range-bound as of the August 3, 2026 data cutoff. After hitting an all-time high of $366.52 in late May, the stock dropped about 23% on June 2, 2026 following the POWER1 miss, bottomed near $240 in mid-June, rebounded to about $350 by June 29, and then consolidated in a roughly $287 to $330 range through July. The stock closed at $307.83 on July 31, 2026, around the middle of that range, with volume below its average.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $307.83 | Google Finance closing price from July 31, 2026. After-hours trading around $312.99 per StockAnalysis. |
| All-time high / resistance | $366.52 | The 52-week and all-time high reached in late May 2026 before the June 1 POWER1 announcement. This is the primary overhead resistance zone. |
| Upper range resistance | $330 | PRAX repeatedly failed near $330 in July (July 14 high $330.17 and July 27 high $330.00). A daily close above $330 would suggest a retest of the $350 level. |
| Near support | $287 to $293 | The July 28 intraday low of $290.09, July 29 low of $287.94, and July 31 low of $293.22 form the near-term support band at the bottom of the July range. |
| Deeper support | $240 to $258 | The June 2026 correction low near $240 and the June 2 crash low of $255.81 mark the deeper support zone that would come into play if the $287 level breaks. |
| Momentum | Neutral, drifting in a range | The stock has been oscillating inside a horizontal band since mid-June. Momentum oscillators likely sit near neutral after the rebound from $240 stalled around $350. |
| Volume | 385,139 on July 31 vs about 500,000 average | Volume was below average on July 31. The highest recent volume was 1.56 million on June 2, 2026, the day of the POWER1 selloff, which marks a distribution signal. |
| Volatility | Beta about 2.74 | Very high beta means PRAX can move 2-3x the market in either direction. Risk controls must account for gap risk on FDA and clinical news. |
| Invalidation | Daily close below $287 | A sustained daily close below $287 with above-average volume would signal a breakdown from the July range and open a path toward the $240 to $258 support zone. |
PRAX AI trading strategy
The PRAX AI trading strategy is a research framework for monitoring a high-volatility, binary-outcome biotech stock. It is not personalized advice. Due to the binary nature of FDA decisions and clinical catalysts, conventional trend-following or mean-reversion setups carry elevated tail risk. Position sizing and catalyst awareness are essential.
Identify upcoming FDA decision dates, clinical data readouts, and earnings dates. Key 2026 catalysts include the Q2 2026 earnings call on August 6, the relutrigine PDUFA target action date of December 27, 2026, and the ulixacaltamide PDUFA target action date of January 29, 2027. Before entry, confirm the event calendar and understand what success and failure look like for each milestone.
Define maximum loss before the catalyst. PRAX dropped about 23% in one day on June 2, 2026 after a Phase 2/3 miss, and it can gap 20-30% on FDA or clinical news. Position size so that a complete loss on a binary event is survivable. Use options or reduced position size around binary events.
If PRAX trades inside its $287 to $330 July range on declining volume with no negative fundamental news, monitor for stabilization near the $287 to $293 support band. A bounce from support with increasing volume could offer a risk-reward entry targeting a retest of the $330 resistance.
Place a stop below $287. If the stock closes below $287 with volume, exit and reassess. Do not add to a losing position hoping for a bounce.
Track cash runway (quarterly burn rate vs $786.87 million of cash and investments as of March 2026), FDA review milestones for relutrigine and ulixacaltamide, elsunersen EMBRAVE3 enrollment and data, vormatrigine program decisions after POWER1, analyst target revisions, insider transactions, and partnership or licensing announcements. The stock can re-rate quickly on any of these factors.
Reduce or exit if FDA issues a complete response letter, cash runway falls below 12 months without a clear financing plan, a lead program shows concerning safety signals, or management guidance suggests trial delays or regulatory setbacks.
Investment research summary
Praxis Precision Medicines is paid by patients and insurers if and when its CNS therapies gain FDA approval and are prescribed. Currently, the company has no approved products and no revenue. Customers pay for clinical hope and pipeline optionality, which is a valuation based on probability-weighted future cash flows.
Praxis holds proprietary Cerebrum small molecule and Solidus ASO platforms, three FDA Breakthrough Therapy Designations, and issued patents covering specific mechanisms for essential tremor and genetic epilepsies. The moat will only be proven if approved therapies show differentiation from existing treatments and competitors cannot easily replicate the mechanism or clinical data package.
The thesis fails if any of the following happen: the FDA issues a complete response letter for relutrigine or ulixacaltamide, a lead program misses its primary endpoint in a late-stage trial (as vormatrigine did in POWER1 on June 1, 2026), a competitor develops a better-tolerated or more effective therapy, safety signals emerge in an expanded population, or the company runs out of cash before reaching profitability.
Management raised capital to reach $786.87 million in cash and investments, advanced relutrigine and ulixacaltamide NDAs to FDA review, secured a Breakthrough Therapy Designation for elsunersen in June 2026, and signed a transdermal delivery collaboration with Remagine Labs in July 2026. The key risk is that clinical-stage management capability does not automatically translate to commercial-stage execution. The company will eventually need a sales force or partnerships to monetize any approved therapies.
CNS disorders represent a large and growing unmet medical need. Essential tremor affects about seven million people in the United States with no drug specifically developed for it, and genetic epilepsies such as SCN2A and SCN8A DEE currently have no approved targeted treatments. Large pharma interest in neurology has increased, creating partnership potential but also competitive pressure.
At about $8.58 billion market cap with no revenue, negative EPS, and accelerating cash burn, conventional margin of safety analysis cannot apply. Net cash of about $785 million covers only about 10% of the market cap. Using analyst consensus, the average target of $601.59 implies about 95% upside, but the Wedbush target of $162 implies about 47% downside from the current price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Reference price | $307.83 latest close | Google Finance PRAX | August 3, 2026 |
| Market capitalization | $8.58 billion, verified as $307.83 x 27.88M shares | Google Finance + financial_rigor.py | August 3, 2026 |
| Shares outstanding | 27.88 million | Google Finance PRAX overview | August 3, 2026 |
| EPS (TTM) | -$13.37 | Google Finance PRAX financials | August 3, 2026 |
| Q1 2026 net loss | -$92.56 million | Google Finance PRAX income statement | August 3, 2026 |
| Q1 2026 operating expenses | $105.86 million | Google Finance PRAX income statement | August 3, 2026 |
| Cash and investments | $786.87 million as of March 31, 2026 | StockAnalysis financials | August 3, 2026 |
| Net cash per share | $32.14 | StockAnalysis financials | August 3, 2026 |
| 52-week high / low | $366.52 / $37.24 | Google Finance PRAX overview | August 3, 2026 |
| Beta | 2.74 | Google Finance PRAX overview | August 3, 2026 |
| Analyst consensus | 16 Buy, 1 Hold, 1 Sell; average target $601.59 | Google Finance PRAX analyst ratings | August 3, 2026 |
| Relutrigine PDUFA target action date | December 27, 2026 | Praxis Precision Medicines press release June 29, 2026 | August 3, 2026 |
| Ulixacaltamide PDUFA target action date | January 29, 2027 | Praxis Precision Medicines press release July 7, 2026 | August 3, 2026 |
| Elsunersen Breakthrough Therapy Designation | Granted June 22, 2026, based on 77% sham-adjusted seizure reduction in EMBRAVE Part A (p=0.015) | Praxis Precision Medicines press release June 22, 2026 | August 3, 2026 |
| Employees | 168 | Google Finance PRAX overview | August 3, 2026 |
This PRAX AI stock analysis is an informational research tool only. It is not investment advice, financial advice, or a recommendation to buy, sell, or hold shares of Praxis Precision Medicines. Forecast scenarios are based on available data at the stated cutoff date and can be wrong. Clinical-stage biotechnology stocks carry binary risk: a single trial result or regulatory decision can cause a large loss of invested capital. Always verify current filings, FDA decision dates, clinical data, cash runway, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
